0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Dronabinol Approved for Use in Anorexia Associated With Weight Loss in Patients with AIDS

Stuart L. Nightingale, MD
JAMA. 1993;269(11):1361. doi:10.1001/jama.1993.03500110025009.
Text Size: A A A
Published online

ABSTRACT

The FDA has approved a supplemental new drug application for dronabinol for anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). The new indication is based on clinical studies involving patients with AIDS, in which the appetite-stimulation effect of dronabinol was sustained for up to 5 months. Dronabinol is manufactured by Unimed Inc, of Buffalo Grove, Ill, under the trade name Marinol. The drug is distributed by Roxane Laboratories Inc of Columbus, Ohio.

Dronabinol is chemically synthesized Δ9-tetrahydrocannabinol, the principal active ingredient in marijuana. Dronabinol was approved initially in 1985 as an antiemetic for treatment of nausea and vomiting associated with cancer chemotherapy (JAMA. 1986;256:817). In January 1991, dronabinol was granted Orphan Drug status for appetite stimulation in patients with AIDS-related weight loss. Orphan Drug status entitles a sponsor to financial incentives for developing drug products for diseases or conditions affecting fewer than 200 000

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();